E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
HBeAg positive and HBeAg negative chronic Hepatitis B virus |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 8.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10008910 |
E.1.2 | Term | Chronic hepatitis B |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate safety and efficacy of peg interferon alpha-2a (40KD) (PEGASYS® ) patients with HBeAg-positive and HBeAg negative Chronic Hepatitis B given for 48 weeks in Lithuania, Latvia and Estonia specific population with Chronic Hepatitis B. |
|
E.2.2 | Secondary objectives of the trial | |
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Age > 18 and ≤ 70 years • HBeAg positive patients: HBV DNA >100,000 copies/ml • HBeAg negative patients: HBV DNA >10,000 copies/ml • HBsAg positive for at least 6 months, anti-HBs negative • Elevated serum ALT > 2x ULN but ≤ 10x ULN as determined by two abnormal values taken >14 days apart during the six months before the first dose of study drug with at least one of the determinations obtained <35 days prior to the first dose. • Patients with chronic hepatitis B, who are treatment-naïve • Negative urine or serum pregnancy test (for women of childbearing potential) documented within the 24-hour period prior to the first dose of study drug. They must be wiling to use reliable contraception during the study and for 4 months after treatment completion.
|
|
E.4 | Principal exclusion criteria |
• Patients who have received IFN based therapy for their chronic hepatitis B before enrolment. • Treatment with a nucleoside analogue within 3 months prior to baseline. • Women with ongoing pregnancy or who are breast feeding. • Evidence of decompensated liver disease including any one of the following: o Serum albumin <3.5 g/dL o Prothrombine time ≥4 seconds prolonged o Serum bilirubin > 34 µmol/L o History of encephalopathy o History of variceal bleeding o Ascites • Co-infection with active hepatitis A, hepatitis C, hepatitis D and/or human immunodeficiency virus (HIV) • History or other evidence of a medical condition associated with chronic liver disease other than viral hepatitis (e.g., hemochromatosis, autoimmune hepatitis, metabolic liver disease, alcoholic liver disease, toxin exposures, thalassemia) • Previous or current hepatocellular carcinoma • History of or other evidence of bleeding from oesophageal varices or other conditions consistent with decompensate liver disease • Alpha-fetoprotein levels of > 100 ng/ml. Patients with values of >20 ng/ml and ≤100 ng/ml may be enrolled, if hepatic neoplasia has been excluded by liver imaging • Neutrophil count <1500 cells/mm3 or platelet count <90,000 cells/mm3 at screening • Haemoglobin < 11.5 g/dl for females and <12.5 g/dl for men at screening • Serum bilirubin level >2 times the upper limit of normal at screening • Serum creatinine level > 1.5 times the upper limit of normal at screening • Severe psychiatric disease including 1. Current uncontrolled psychiatric disease, especially depression 2. Previous documented suicide attempts 3. Any patient with history of hospitalization for psychiatric disease, or current antidepressant medication or major tranquilizer should be reviewed by consultant psychiatrist regarding suitability for interferon therapy. • History of a severe seizure disorder or current anticonvulsant use • History of immunologically mediated disease, chronic pulmonary disease associated with functional limitation, severe cardiac disease, major organ transplantation or other evidence of severe illness, malignancy, or any other conditions which would make the patient, in the opinion of the investigator, unsuitable for the study • Thyroid disease uncontrolled by prescribed medications • Evidence of severe retinopathy (e.g. CMV retinitis, macular degeneration) • Evidence of drug abuse within one year of study entry • Alcohol intake of more than 3 standard drinks per day for men and 2 standard drinks for women (1 standard drink contains 10 g alcohol) • Patients included in another trial or having been given investigational drugs within 12 weeks prior to screening • Inability or unwillingness to provide informed consent or abide by the requirements of the study, including scheduled blood tests and clinic appointments.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
• HBV DNA reduction 10-fold |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 5 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 10 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Enrolment will be open until the sites have enrolled 50 patients, but not more then 20 months after the first patients' enrolment in to the study. The first patient was recruited in April 2007. End of the study is planned in June 2010. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |